{"id":55899,"date":"2026-01-30T13:23:46","date_gmt":"2026-01-30T05:23:46","guid":{"rendered":"https:\/\/flcube.com\/?p=55899"},"modified":"2026-01-30T13:23:47","modified_gmt":"2026-01-30T05:23:47","slug":"tyk-medicines-asandeutertinib-gets-china-priority-review-for-nsclc-brain-metastases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55899","title":{"rendered":"TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>TYK Medicines, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2410:HKG\">HKG: 2410<\/a>) announced that its Category\u202f1 drug <strong>asandeutertinib (TY\u20119591)<\/strong>, a third\u2011generation EGFR tyrosine kinase inhibitor (TKI), has been granted <strong>priority review status<\/strong> by the <strong>Center for Drug Evaluation (CDE)<\/strong> for first\u2011line treatment of <strong>locally advanced or metastatic NSCLC with CNS metastases<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>TYK Medicines, Inc. (2410.HK)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Asandeutertinib (TY\u20119591)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>CDE Priority Review Status<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Third\u2011generation EGFR TKI (deuterated osimertinib derivative)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First\u2011line NSCLC with EGFR exon\u202f19 deletion or L858R mutation + CNS metastases<\/td><\/tr><tr><td><strong>Key Features<\/strong><\/td><td>High bioavailability, effective brain penetration<\/td><\/tr><tr><td><strong>Market Gap<\/strong><\/td><td>No third\u2011generation EGFR\u2011TKI approved globally for NSCLC brain metastasis<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>NDA under priority review<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-differentiation-amp-unmet-need\">Clinical Differentiation &amp; Unmet Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CNS Efficacy:<\/strong> Asandeutertinib is a <strong>deuterated derivative of osimertinib<\/strong> optimized for superior brain penetration, addressing the critical unmet need of <strong>CNS metastases<\/strong> in EGFR\u2011mutant NSCLC<\/li>\n\n\n\n<li><strong>Market Void:<\/strong> Currently, no third\u2011generation EGFR\u2011TKI holds a <strong>global approval<\/strong> specifically for NSCLC brain metastasis indication<\/li>\n\n\n\n<li><strong>Data Limitations:<\/strong> Existing TKIs (osimertinib, almonertinib, furmonertinib) rely on <strong>retrospective subgroup analyses<\/strong> with small sample sizes (<strong>13\u201128 cases<\/strong>), lacking statistical power for confirmatory conclusions<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Priority review accelerates NMPA timeline; prospective, randomized controlled trials still required for label expansion and global validation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China NSCLC Market:<\/strong> <strong>~800,000 new NSCLC cases<\/strong> annually; <strong>20\u201140%<\/strong> develop brain metastases, representing <strong>\u00a55\u202fbillion<\/strong> (~US$700\u202fmillion) addressable market<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> Asandeutertinib\u2019s CNS\u2011optimized profile could differentiate from standard EGFR\u2011TKIs, particularly in front\u2011line setting where CNS involvement is common<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a51.2\u20131.8\u202fbillion<\/strong> (US$170\u2013250\u202fmillion) peak annual sales in China if approved, based on premium pricing and unmet need<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Priority review signals regulatory confidence; validates TYK\u2019s deuteration platform for CNS\u2011penetrant therapeutics<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> NMPA approval decision expected <strong>H2\u202f2026<\/strong>; global Phase\u202fIII program may follow for ex\u2011China markets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory review timelines, clinical development plans, and commercial expectations for asandeutertinib. Actual results may differ due to NMPA review outcomes, clinical trial risks, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TYK Medicines, Inc. (HKG: 2410) announced that its Category\u202f1 drug asandeutertinib (TY\u20119591), a third\u2011generation EGFR&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55900,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,1586,80,33,395],"class_list":["post-55899","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-hkg-2410","tag-priority-reviews","tag-tkis-egfr-vegf-btk-etc","tag-tyk-medicines"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"TYK Medicines, Inc. (HKG: 2410) announced that its Category\u202f1 drug asandeutertinib (TY\u20119591), a third\u2011generation EGFR tyrosine kinase inhibitor (TKI), has been granted priority review status by the Center for Drug Evaluation (CDE) for first\u2011line treatment of locally advanced or metastatic NSCLC with CNS metastases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55899\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases\" \/>\n<meta property=\"og:description\" content=\"TYK Medicines, Inc. (HKG: 2410) announced that its Category\u202f1 drug asandeutertinib (TY\u20119591), a third\u2011generation EGFR tyrosine kinase inhibitor (TKI), has been granted priority review status by the Center for Drug Evaluation (CDE) for first\u2011line treatment of locally advanced or metastatic NSCLC with CNS metastases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55899\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T05:23:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T05:23:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3008.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55899#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55899\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases\",\"datePublished\":\"2026-01-30T05:23:46+00:00\",\"dateModified\":\"2026-01-30T05:23:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55899\"},\"wordCount\":353,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55899#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3008.webp\",\"keywords\":[\"Cancer\",\"HKG: 2410\",\"Priority reviews\",\"TKIs (EGFR VEGF BTK etc.)\",\"TYK Medicines\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55899#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55899\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55899\",\"name\":\"TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55899#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55899#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3008.webp\",\"datePublished\":\"2026-01-30T05:23:46+00:00\",\"dateModified\":\"2026-01-30T05:23:47+00:00\",\"description\":\"TYK Medicines, Inc. (HKG: 2410) announced that its Category\u202f1 drug asandeutertinib (TY\u20119591), a third\u2011generation EGFR tyrosine kinase inhibitor (TKI), has been granted priority review status by the Center for Drug Evaluation (CDE) for first\u2011line treatment of locally advanced or metastatic NSCLC with CNS metastases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55899#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55899\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55899#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3008.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3008.webp\",\"width\":1080,\"height\":608,\"caption\":\"TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55899#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases - Insight, China&#039;s Pharmaceutical Industry","description":"TYK Medicines, Inc. (HKG: 2410) announced that its Category\u202f1 drug asandeutertinib (TY\u20119591), a third\u2011generation EGFR tyrosine kinase inhibitor (TKI), has been granted priority review status by the Center for Drug Evaluation (CDE) for first\u2011line treatment of locally advanced or metastatic NSCLC with CNS metastases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55899","og_locale":"en_US","og_type":"article","og_title":"TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases","og_description":"TYK Medicines, Inc. (HKG: 2410) announced that its Category\u202f1 drug asandeutertinib (TY\u20119591), a third\u2011generation EGFR tyrosine kinase inhibitor (TKI), has been granted priority review status by the Center for Drug Evaluation (CDE) for first\u2011line treatment of locally advanced or metastatic NSCLC with CNS metastases.","og_url":"https:\/\/flcube.com\/?p=55899","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-30T05:23:46+00:00","article_modified_time":"2026-01-30T05:23:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3008.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55899#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55899"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases","datePublished":"2026-01-30T05:23:46+00:00","dateModified":"2026-01-30T05:23:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55899"},"wordCount":353,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55899#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3008.webp","keywords":["Cancer","HKG: 2410","Priority reviews","TKIs (EGFR VEGF BTK etc.)","TYK Medicines"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55899#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55899","url":"https:\/\/flcube.com\/?p=55899","name":"TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55899#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55899#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3008.webp","datePublished":"2026-01-30T05:23:46+00:00","dateModified":"2026-01-30T05:23:47+00:00","description":"TYK Medicines, Inc. (HKG: 2410) announced that its Category\u202f1 drug asandeutertinib (TY\u20119591), a third\u2011generation EGFR tyrosine kinase inhibitor (TKI), has been granted priority review status by the Center for Drug Evaluation (CDE) for first\u2011line treatment of locally advanced or metastatic NSCLC with CNS metastases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55899#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55899"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55899#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3008.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3008.webp","width":1080,"height":608,"caption":"TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55899#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3008.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55899"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55899\/revisions"}],"predecessor-version":[{"id":55901,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55899\/revisions\/55901"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55900"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}